To The Moon

$Eli Lilly(LLY)$ is making headlines today after a stellar first-quarter earnings report that surpassed analyst expectations. The pharmaceutical giant not only reported impressive revenue and profit growth, but also hiked its full-year guidance, reflecting strong sales of its blockbuster drugs Mounjaro and Zepbound.

Financial Highlights

• Earnings per share: $2.58 adjusted vs. $2.46 expected (beat)

• Revenue: $8.77 billion vs. $8.92 billion expected (slight miss)

• Full-year adjusted EPS guidance: Raised to $13.50-$14.00 from $12.20-$12.70

• Full-year revenue guidance: Increased to $42.4-$43.6 billion from $40.4-$41.4 billion

Key Takeaways

• Mounjaro and Zepbound Drive Growth: Sales of Mounjaro, the company's diabetes drug, continue to impress. Zepbound, the newly launched weight-loss treatment, also showed strong initial sales despite supply shortages. Analysts predict Zepbound could become the biggest drug of all time.

• Strong Revenue Growth: Overall revenue grew 26% year-over-year, surpassing expectations despite a slight miss on the top line.

• Increased Guidance Bullish Signal: The upward revision to full-year guidance demonstrates Lilly's confidence in its future performance.

Technical Analysis Confirms Bullish Sentiment

LLY Daily Chart

Adding to the positive news, Eli Lilly's stock price has been consolidating for the past 80 days, currently trading near the top of this range. This technical pattern is often seen as a bullish signal, suggesting a potential breakout towards higher prices.

The increased availability of incretin drugs like Mounjaro in the second half of the year is expected to further accelerate revenue growth. Investor sentiment is clearly positive, with shares of Lilly jumping in premarket trading. The stock is already up over 30% year-to-date, fueled by the success of its weight loss and diabetes treatments.

Overall, Eli Lilly's strong earnings report, raised guidance, and bullish technical analysis paint a bright picture for the company's future. Investors should closely monitor the stock's price movement in the coming days to see if it can break out of its consolidation and continue its upward trajectory.

Follow @TigerStars @CaptainTiger @MillionaireTiger @TigerPM @Daily_Discussion @Tiger_comments @TigerSG

Disclaimer:This post reflects my personal opinions and should not be considered as financial advice. Always conduct thorough research before making any investment decisions.